Impact of stressors and stress responses on the daily life of college students with migraine / 四川精神卫生

BackgroundStress is closely related to migraine attacks， however， previous studies on stressors， stress responses and their impact on the daily life of college students with migraine remain unclear. ObjectiveTo explore the impact of stressors and stress responses on the daily life of college students with migraine， in order to provide references for improving daily life of this population. MethodsFrom August 2018 to August 2019， 458 students from North Sichuan Medical College who met the International Classification of Headache Diseases third edition （ICHD-3）， were selected using random sampling method. General data and headache characteristics were collected. The 6-item Headache Impact Test Questionnaire （HIT-6） was used to assess the impact of migraine on daily life. Student-Life Stress Inventory （SLSI） was used to assess the stressors and stress responses. Hamilton Anxiety Scale （HAMA） and Hamilton Depression Scale-24 item （HAMD-24） were used to assess anxiety and depressive symptoms. Pearson correlation analysis were used to examine the relationship between HIT-6 score and scores on various scales. Multiple linear regression was used to analyze the influencing factors on daily life in college students with migraine. ResultsIn the SLSI， stressors in the dimensions of frustration （r=0.138， P<0.01）， conflict （r=0.168， P<0.01）， pressure （r=0.157， P<0.01）， change （r=0.148， P<0.01）， self-imposed （r=0.158， P<0.01） ， as well as physiological response （r=0.256， P<0.01）， emotional response （r=0.241， P<0.01）， behavioral response （r=0.164， P<0.01）， HAMA total score （r=0.192， P<0.01）， dHAMD-24 total score （r=0.250， P<0.01）， and SLSI total score （r=0.250， P<0.01）， were positively correlated with HIT-6 score. Cognitive response （r=-0.104， P<0.05） was negatively correlated with HIT-6 score. Stepwise multiple linear regression revealed that physiological response （β=0.140， P<0.05）， anxiety （β=0.159， P<0.05）， and cognitive response （β=-0.091， P<0.05） could predict the impact on daily life of college students with migraine. ConclusionPhysiological response， cognitive response and anxiety may be the independent influencing factors on the daily life of college students with migraine. ［Funded by Nanchong City University Science and Technology Strategic Cooperation Project （number， NSMC20170420）］

Cefalea por abuso de medicamentos y sus marcadores clínicos / Medication overuse headache and its specific clinical markers

Resumen Introducción: Los marcadores clínicos de la cefalea por uso excesivo de medicación (CMA) se basan en la clasificación de las cefaleas desarrollada por la Sociedad Internacional de Cefaleas (IHS). Esta clasificación incluye sólo dos criterios: la frecuencia de los días de cefalea debe ser de 15 o más días al mes durante al menos tres o más meses; - y el número de días de uso excesivo de la medicación debe ser de 10 o 15 días al mes dependiendo del tipo de medicación. Sin embargo, los pacientes suelen tener otros marcadores clínicos asociados distintos, que la mayoría de los médicos pasan por alto durante la evaluación inicial. Metodología: Este estudio es un estudio prospectivo, longitudinal y observacional de 76 pacientes ingresados en la Unidad de Cefaleas del hospital DIPRECA. Todos ellos fueron diagnosticados de HMO según los criterios establecidos por su ICHD III beta.(1) Los pacientes recibieron un tratamiento estándar que incluía desintoxicación y medicación preventiva y fueron seguidos durante 6 meses. Se registraron los síntomas de interés en cada visita de seguimiento clínico y se administraron escalas de evaluación como Zung, MIDAS, HIT-6. Resultados: Los medicamentos sobreutilizados incluyeron antiinflamatorios no esteroideos (AINE), triptanes y cornezuelos. Los síntomas clínicos más significativos asociados fueron: despertar por la mañana con dolor de cabeza, despertar al paciente al amanecer por dolor de cabeza, dificultades de atención, depresión, dolor cervical y síndrome de dolor miofascial. Todos los síntomas mejoraron significativamente al iniciar el tratamiento, al igual que la calidad de vida medida por las escalas MIDAS y HIT-6. Discusión: Al evaluar a los pacientes con HMO, hay que tener en cuenta tanto los criterios diagnósticos de la ICHD III beta como los síntomas comunes y específicos que se observan en la mayoría de los casos de HMO.

Introduction: Clinical markers of medication overuse headache (MOH) are based on headache classification developed by the International Headache Society (IHS). This classification include only two criteria: frequency of headache days must be 15 or more days per month for at least three or more months; - and the number of days of overuse medication must be either 10 or 15 days per month depending on the type of medication. However, patients often have others distinct associated clinical markers, which are overlooked by most physicians during the initial evaluation. Methodology: This study is a prospective, longitudinal and observational study of 76 patients admitted to DIPRECA´s hospital Headache Unit. They were all diagnosed with, MOH according to the criteria established by the his ICHD III beta.(1) Patients were given standard treatment including detoxification and preventive medications and followed for 6 months. Symptoms of interest were recorded in at each clinical monitoring visit and assessment scales such as Zung, MIDAS, HIT-6 were administered. Results: Overused medications included nonsteroidal anti-inflammatory drugs (NSAIDs), triptans and ergots. The most significant clinical symptoms associated were: awaking in the morning with headache, awaking the patient at dawn by headache, attention difficulties, depression, cervical pain and myofascial pain syndrome. All symptoms significantly improved when treatment began, as did quality of life as measured by MIDAS and HIT-6 scales. Discussion: In evaluating patients with MOH consider both the ICHD III beta diagnostic criteria and the common and specific symptoms seen in most cases of MOH.

Effects of therapeutic and aerobic exercise programs in temporomandibular disorder-associated headaches

Abstract Objective To assess the effects of three 8-week exercise programs on the frequency, intensity, and impact of headaches in patients with headache attributed to temporomandibular disorder (TMD). Methodology Thirty-six patients diagnosed with headache attributed to TMD participated in the study and were divided into three groups of 12 patients: a therapeutic exercise program (G1, mean age: 26.3±5.6 years), a therapeutic and aerobic exercise program (G2, mean age: 26.0±4.6 years), and an aerobic exercise program (G3, 25.8±2.94 years). Headache frequency and intensity were evaluated using a headache diary, and the adverse headache impact was evaluated using the Headache Impact Test (HIT-6). The intensity was reported using the numerical pain rating scale. These parameters were evaluated twice at baseline (A01/A02), at the end of the 8-week intervention period (A1), and 8-12 weeks after the end of the intervention (A2). Results At A1, none of the G2 patients reported having headaches, in G1, only two patients reported headaches, and in G3, ten patients reported headache. The headache intensity scores (0.3 [95% CI: -0.401, 1.068]), (0.0 [95% CI: -0.734, 0.734]) and HIT-6 (50.7 [95% CI: 38.008, 63.459]), (49.5 [95% CI: 36.808, 62.259]), significantly decreased in G1 and G2 at A1. At A2 headache intensity scores (0.5 [95% CI: -0.256, 1.256]), (0.0 [95% CI: -0.756, 0.756]) and HIT-6 (55.1 [95% CI: 42.998, 67.268]), (51.7 [95% CI: 39.532, 63.802]) in G1 and G2 haven't change significantly. The effects obtained immediately after the completion of the intervention programs were maintained until the final follow-up in all groups. Conclusion The programs conducted by G1 (therapeutic exercises) and G2 (therapeutic and aerobic exercise) had significant results at A1 and A2.

Evaluation of the effect of botulinum neurotoxin type A (BoNT/A) on daily activity performance in chronic migraine patients using VAS, MIDAS AND HIT-6 tests

@#Background & Objectives: According to ICHD-III beta 2013 criteria, chronic migraine is defined as having headaches more than 15 times a month, for a period of more than 3 months, at least 8 must have migrainous features or good response to migraine-specific treatment; there must also be a history of 5 or more migraine attacks. The aim of the present study was to evaluate the effect of Botulinum Neurotoxin A (BONT/A) on headache and daily activities in chronic migraine patients using VAS, MIDAS and HIT-6 tests. Methods: Twenty five patients admitted to Hospital Department of Neurology were reviewed retrospectively. In order to evaluate the severity of headache and effects on daily performance, MIDAS (Migraine Disability Assessment Test), VAS (Visual Analogue Scale for Pain) and HIT-6 results after the baseline assessment, first and second administration of (BONT/A) were examined retrospectively from patients’ records. Results: VAS, MIDAS and HIT-6 scores were compared after baseline assessment and the first and second administrations. Results showed that VAS, MIDAS and HIT-6 scores decreased. This difference was statistically significant (p<0.05). Correlation analysis was conducted and significant correlations between scores on these three tests were found.Conclusions: The results showed that BoNT/A is an important and effective treatment option for chronic migraine patients not responding to migraine-specific prophylactic treatment and having alterations in daily life due to frequency and severity of pain.

Differences in Clinical Features and Disability according to the Frequency of Medication Use in Patients with Chronic Migraine

BACKGROUND AND PURPOSE: Chronic migraine (CM) has a significant impact on daily activities, and analgesic overuse is a major contributing factor to migraine transformation. Limited information is available on the functional consequences of CM stemming from analgesic overuse. This study evaluated the impact of the frequency of analgesic medication use on headache-related disability and clinical features in patients with CM. METHODS: Patients with CM were enrolled consecutively and classified into two groups according to their frequency of medication use: or =15 days/month (CM-MH, n=68). All patients completed a structured questionnaire concerning the clinical features of their migraine, a validated version of the Migraine Disability Assessment questionnaire (MIDAS), and the Headache Impact Test-6 (HIT-6). RESULTS: The pain intensity, as measured by a visual analog scale, was greater in the CM-MH group than in the CM-ML group (8.5+/-0.2 vs. 7.7+/-0.3, mean+/-SD; p<0.05). In the disability domain, the MIDAS scores were significantly higher for CM-MH patients than for CM-ML patients (47.6+/-4.8 vs. 26.8+/-4.5, p<0.01). The impact from migraine, as measured by the HIT-6, was greater for CM-MH patients than for CM-ML patients (65.6+/-1.0 vs. 62.1+/-1.0, p<0.05). CONCLUSIONS: Our results indicate that the headache pain intensity and disability are greater in patients with CM who use medication frequently.